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Abstract
The qualification of new knowledge is one of the oldest prob-
lems in experimental medicine that provides a link between 
fundamental discovery, hypothesis, ‘proof of concept’ pre-
clinical studies and development of clinical trials. The biggest 
challenge in animal models is the proper evaluation of all the 
aspects that are crucial in specific studied pathologies as well 
as the prediction of their progression. The aim of this review 
was to describe and discuss the rat animal model of heart 
transplant. The rat model of heart transplantation is an ex-
cellent yet underestimated method of research of prevention, 
monitoring and treatment of acute and chronic, immune and 
nonimmune response to organ transplantation. Despite being 
a technically and logistically demanding model, it provides 
a tool for reproducible experiments with longterm animal sur-
vival and excellent graft survival. 
Key words: animal model, heart transplantation, sex differ-
ences.
Streszczenie
Określenie jakości i poziomu przydatności nowej wiedzy jest 
jednym z najstarszych problemów medycyny eksperymentalnej, 
która zapewnia powiązanie między fundamentalnym odkry-
ciem, hipotezą, przedklinicznymi badaniami „dowodu słuszno-
ści” a rozwojem badań klinicznych. Największym wyzwaniem 
w modelach zwierzęcych jest właściwa ocena wszystkich aspek-
tów, które są kluczowe w poszczególnych badanych patologiach, 
a także przewidywanie ich progresji. Celem tej pracy było opi-
sanie i omówienie modelu przeszczepu serca u szczura. Model 
ten jest doskonałą, lecz nadal niedocenianą, metodą badań 
w zapobieganiu, monitorowaniu, a także leczeniu ostrej oraz 
przewlekłej odpowiedzi immunologicznej i nieimmunologicznej 
po przeszczepieniu narządu. Mimo że jest to model wymagający 
pod względem technicznym i logistycznym, umożliwia uzyskać 
powtarzalne eksperymenty z długoterminowym przeżyciem nie 
tylko zwierząt, lecz także przeszczepionych narządów.
Słowa kluczowe: model zwierzęcy, przeszczepienie serca, 
różnice płci.
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Introduction
The qualification of new knowledge is one of the oldest 
problems in experimental medicine. Producing a standard-
ized tool to test the hypothesis has been a primary goal of 
scientific research. The definition of “experimental model” 
has been evolving through various areas of research, from 
“the simple representation of the reality derived only from 
abstraction” through “an act of spirit in which we can in-
spire ourselves” (from the 17th century, Blaise Pascal) to the 
modern one, which describes it as “any example that uses 
the analytical method for research and hypothesis inquiry”. 
Experimental medicine provides a link between fundamen-
tal discovery, hypothesis, ‘proof of concept’ preclinical stud-
ies and development of clinical trials [1].
Using experimental animal models in medical research 
not only furthers the understanding of the mechanism 
and progression of the disease or any physiological distur-
bances, but also provides the possibility of introducing new 
methods of surgical, pharmacological or other treatments 
that offer enhanced patient outcomes (efficacy and safety). 
The typical model involves animals in which physiological 
or pathological processes are sufficiently similar to those in 
humans and are either induced or occur naturally. The big-
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all the aspects that are crucial in specific studied patholo-
gies as well as the prediction of their progression. 
Aim
The aim of this review was to describe and discuss the 
rat animal model of heart transplant, which, with the pro-
posed modification, provides an excellent and reproducible 
modality to study organ preservation and effective replace-
ment.
Discussion
From all causes of different organ failure, cardiovascu-
lar diseases are the leading cause of morbidity and death 
in developed countries. The different multifactorial pathol-
ogies, including congenital and acquired anatomical distur-
bances in blood flow and atherothrombosis of the coronary 
arteries causing ischemic heart disease, are the reasons for 
heart failure at the end stage. Heart transplant is an ac-
cepted treatment modality in the end stage of heart failure. 
Transplantology is the field of medicine interested in 
replacing or adding cells or entire organs in order to re-
store the function of the human body. The main problem in 
transplantation procedures using any cells or organs taken 
from different species is the immunological response to the 
foreign tissue. Autotransplantation, the process in which 
the transplanted tissue comes from the recipient, is the 
only method completely safe from rejection.
There is no immunological acceptance of the living 
tissue transplanted from different species, a procedure 
called xenotransplantation. In those experimental models 
a strong anti-rejection treatment is used that often compli-
cates the postoperative period with its severe side effects, 
and ultimately a loss of the transplanted organ or tissue 
occurs. 
The fully accepted method of obtaining organs is pro-
curement from a representative of the same species, called 
allotransplantation. However, even the allografts are not 
immunologically compatible, and an anti-rejection treat-
ment must be implemented, although it generally provides 
better results and less severe side effects. At the time of 
transplantation, the battle between the immune response 
of the recipient and the side effects of the pharmacologi-
cal treatment begins, and it must be balanced in order to 
keep the graft fully functional. The survival of the graft is 
unpredictable and depends on the various significant and 
chronic changes in its physiology. The unique immune re-
sponse depends not only on an immunological compatibil-
ity between the donor and the recipient, but also on the 
age, gender and comorbidities that have an impact on im-
munological condition. In the era of organ donor shortages, 
medical research is striving to find the safest and most effi-
cient method to preserve graft function as long as possible. 
In 1905, Alexis Carrel worked on an animal model of 
heterotopic heart transplant without success, and it was 
not until 55 years later that Richard R. Lower and Norman 
E. Shumway successfully performed an orthotopic heart 
transplant in a canine model. In 1967, Christian N. Barnard 
was the first to transplant the human heart with success 
following his work on animal models. Since then research 
in heart transplantation has developed enormously. 
Nowadays, animal models of organ and tissue trans-
plantation provide the ultimate preclinical assessment for 
the study of rejection mechanisms. Both large and small 
animals have been used in this research. There are three 
main factors in choosing the animal model: first, the sci-
entific hypothesis, second, the laboratory’s ability to main-
tain the selected animal species, and third, the degree of 
similarity to the human anatomy and physiology. The use 
of either small or big animals can be limited by the techni-
cal problems due to specific laboratory equipment and the 
researchers’ skills. All these aspects should be taken into 
consideration when choosing the animal model [2].
There are two main models of heart transplantation: 
orthotopic (the donor heart is placed in an anatomically 
correct position) and heterotopic (the donor heart is placed 
in a location other than the mediastinum). The orthotopic 
transplantation is a gold standard for the study of heart 
transplantation. It requires not only the use of cardiopul-
monary bypass, but also a high level of surgical skills and 
larger animals, being almost impossible to perform in ro-
dents. This model has traditionally been chosen for the 
study of organ preservation, immunology, graft rejection 
and ischemia/reperfusion injury. 
While heterotopic heart transplantation is uncommon-
ly used in transplantology research due to the nonphysio-
logical blood flow (limited to coronary arteries and venous 
systems), it is widely used for studies of ischemia/reperfu-
sion injury, immunosuppression, prevention of rejection, 
or graft coronary vasculopathy evaluation. The main tech-
nical difficulty comes from the need to use microsurgery 
techniques, especially in rodents. The undeniable advan-
tage of this model is that the recipient may remain com-
pletely healthy whether or not the heterotopic donor heart 
survives, whereas the transplanted heart behaves as an 
aorto-caval fistula of little hemodynamic consequence to 
the recipient. 
Rats are popular in transplantology research because of 
their size, low maintenance of the model, reproducibility, 
low cost and ease of handling in most laboratories: the rat 
reaches sexual maturity between the 80th and 100th day of 
life and the fertility decreases after 5–6 l; the pregnancy 
lasts 21–23 days and depending on the strain, 4–16 pups 
are born. There are a variety of strain types that provide re-
searchers with many options when designing experiments. 
Because of the homozygosity of the strains, it is neces-
sary to take into account their adaptability impairment in 
comparison with unselected strains (heterozygotes-wild 
strains), which requires the creation of optimal and stable 
handling conditions.
To avoid intra-species variability in medical research 
inbred strains (genetically almost identical) are widely 
used. The inbred strains include consomic (chromosomal 
substitution), congenic (chromosomal region substitu-
tion), recombinant inbred, transgenic and mutant strains. 
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For transplantology research, a simple inbred strain is used 
to reduce acute intra-species dependent immunology re-
sponses as well as the need for the administration of an-
tirejection drugs. To achieve a simple inbred strain at least 
20 generations of brothers and sisters have to be mated, 
and after that each individual can be treated effectively as 
a clone (at which point at least 98.6% of the loci in an indi-
vidual of the strain will be homozygous) [3]. The knock-out 
rat is a genetically engineered rat with a single gene turned 
off through a targeted mutation. Because the technology of 
creating knock-out rats is very recent, models using mutant 
rats are only just emerging.
Despite all the limitations the rat model is still attrac-
tive because of the availability of a larger number of geneti-
cally well-characterized inbred and congenic strains.
Most of the strains in research are derived from the al-
bino Wistar rat. Other common strains are Sprague-Daw-
ley, Fisher 344, Holtzman albino, Long Evans, and Lister 
black hooded rats. To avoid complications, the study design 
should consider the appropriate strain such as a strain re-
sistant to respiratory infections. 
The rat heterotopic heart transplantation is a repro-
ducible model for studies on transplantation immunology, 
mechanisms and treatment of allograft acute rejection and 
vasculopathy as a result of chronic rejection. This model is 
attractive because it uses a vascularized organ, which is 
more relevant to clinical transplantation than tissue grafts. 
Operative techniques
The technique of heterotopically transplanting fully vas-
cularized hearts from one rat into the abdomen of another 
rat was originally described in 1933 by Mann, introduced by 
Abbott et al. [4]. They however were dealing with paraple-
gia as the main complication of the procedure with resul-
tant wastage of time and animals. Finally, in 1969 Ono and 
Lindsay introduced an improved model of the heterotopic 
heart transplantation that minimized the risk of paraplegia. 
In that model, the heart is harvested from the donor after 
heparinization and preserved in cardioplegia. After recipi-
ent abdominal vessel preparation and clamping, the heart 
is placed transversely in the left side of the abdominal cav-
ity and donor aorta and pulmonary artery are connected 
end-to-side to the recipient aorta and inferior vena cava 
(IVC) using a running suture. This technique requires mi-
crosurgical equipment including an operative microscope, 
surgical instruments (jeweler’s forceps, angled Castroviejo 
iris scissors and straight Castroviejo needle holder) and 
very fine sutures, e.g. 10-0, usually used in ophthalmol-
ogy. After releasing the clamps, the heart starts to contract 
spontaneously. In order to be successful, the time of the 
vessel clamping during implantation should not exceed 
30 minutes. The operative technique is described in detail 
in their publication and is still widely used [5].
Despite its simplicity and reproducibility, the model has 
limitations as a consequence of a lack of hemodynamic 
work of the left ventricle (LV): stroke volume and LV pres-
sure close to zero, deep structural and metabolic changes, 
different myosin structure, impaired enzymatic activity, re-
duced total protein content in the heart muscle and chang-
es in heart weight. This results in heart failure and finally 
graft atrophy [6]. Smith et al. reported a 15% to 25% reduc-
tion in graft size relative to the native heart in 14 days and 
a 30% to 60% reduction by day 60 [7].
In 1991, Klein et al. presented a modification of Ono’s 
model. They proposed the insertion of a balloon to the left 
ventricle to sustain the isovolumic work [8]. This solved the 
problem with atrophy but did not preserve the ventricle 
from fibrosis and restriction. To improve the filling of the 
ventricle with blood, an aortic regurgitation was created 
by puncturing one of the aortic cusps. This modification of 
the model was described by Spencer et al. [6] and greatly 
changed the LV loading and enforced the ventricle to ac-
tively pump the returning blood. The degree of aortic re-
gurgitation and the impact on graft workload needed to be 
further improved [9].
Yokoyama et al. [10] presented a different model of 
loaded LV-ASD creation, resection of the tricuspid valve, 
pulmonary artery ligation-donor aorta anastomosis to the 
recipient’s abdominal aorta and the donor right atrium to 
the recipient’s IVC respectively. The main difference is in 
oxygenation in the coronary circulation (Figure 1).
Figure 1. Models of the heart transplant: A – Ono. B – Spencer and Śliwka. C – Yokoyama
A B C
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Tang-Quan et al. [11] compared non-volume-loaded to 
Yokoyama’s volume-loaded model of heterotopic heart 
transplantation and confirmed in both echocardiogra-
phy and Langendorff perfusion that those volume loaded 
hearts undergo chronic ischemia because of coronary per-
fusion with partly deoxygenated blood and are not recom-
mended in preclinical transplant studies.
Therefore, the most optimal model requires the oxy-
genated coronary blood flow and ventricle loading, as de-
scribed by Śliwka et al. and Spencer et al. [6, 9].
All the modifications resulted in a well-established het-
erotopic heart transplant model of low mortality and ex-
tended graft survival that facilitates research of functional 
integrity of a whole organ and the effects of immunosup-
pressive drugs and chronic rejection. 
Function monitoring
Palpation
There are two basic methods used to monitor the func-
tion of the heterotopically transplanted heart, the everyday 
palpation through the abdominal wall and electrocardi-
ography at defined points in the follow-up period. Palpa-
tion of the strength of cardiac contractility is assessed on 
a 4-degree scale: 4+ the strongest and 1+ the weakest. 
The first manifestation of acute rejection is a decline in 
strength and occurs six to eight days after heart transplan-
tation (“time of impulse decline”, TID) of an H-2 and non-
H-2 mismatched graft if no immunosuppression was used. 
Usually 2–3 days after TID the heartbeat is hardly or not 
palpable and the rejection process is completed [4].
Electrocardiography
The electrocardiographic signs of the rejection are volt-
age deflections of less than 3 mm in each electrical vector 
tested. These methods of graft rejection assessment are 
reproducible and corelate well with graft histology [12].
Ultrasound evaluation
The serial echocardiography is not sensitive enough to 
detect and assess early signs of graft rejection. The ven-
tricular wall thickness and ejection fraction remain almost 
unchanged at the early phase of intra-graft immunological 
response. Fischer et al. presented a novel imaging platform 
to diagnose and monitor acute and chronic graft rejection 
with the possibility of predicting this process. They used 
contrast-enhanced ultrasonography (CEUS) in combina-
tion with gas-filled microbubbles to detect and assess the 
changes in micro-vascular perfusion as the effect of the re-
jection process and confirmed its utility in a murine model 
of heart transplant research. Furthermore, they created 
a high-resolution perfusion map of CEUS signals to detect 
impaired blood flow in the graft microvasculature [13].
Advances in ultrasound technology, e.g. VEVO 3100, in-
cluding ultra-high-frequency transducers up to 70 MHz, im-
provements in signal processing and novel post-acquisition 
analysis such as diastolic dysfunction, cardiac strain (longi-
tudinal, radial, and circumferential synchrony and deforma-
tion globally or regionally) as well as image-guided cardiac 
injections and assessment of myocardial oxygen satura-
tion, have all improved the imaging quality and utility of 
ultrasound systems. 
Nonetheless, standard ultrasound with assessment 
confined to only the left ventricle ejection fraction is still 
widely used in heart transplant research. 
Isolated heart perfusion
For better evaluation of the graft function, the isolated 
heart perfusion is one of the most popular experimental 
models in regard to the quality and quantity of the pro-
vided data (spectrum of pharmacological, biochemical, 
physiological and morphological measurements). The main 
investigational advantage is that the measurements can be 
made in the absence of the confounding effects of other 
organs and circulating neurohormones. For both Langen-
dorff perfusion (isolated retrograde perfusion) and work-
ing heart special equipment and experience are required 
to record and analyze multiple cardiac parameters such as 
left ventricular pressure, perfusion pressure, coronary flow, 
cardiac electrical activity and heart rate in real time. The 
isolated heart can be used in transplantology research to 
study coronary reactivity, endothelial and smooth muscle 
function as a consequence of the graft vasculopathy and 
ischemia [14].
Rejection in rats
Most rodents have major histocompatibility complex 
(MHC) variants similar to those of humans, determining 
the immune responsiveness of different strains to isolated 
antigens and inducing rejection. In rats it is called RT1 with 
the location of 20p12. Gene products of different regions 
within the rat MHC-class I or II antigens influence the type 
of rejection if an organ is transplanted across isolated class I 
or class II disparities. The RT1 complex encodes two class I 
molecules, RT1.A and RT1.C, and two class II molecules, 
RT1.B and RT1.D. Barran and McMaster described the isola-
tion of the RT1.B α gene in Sprague-Dawley rats using RT1.B 
α chain cDNA as a hybridization probe. They determined 
the coding and the majority of the intron DNA sequence 
and confirmed that this gene is equivalent to that of H-2 in 
mice and HLA α chain in humans [15].
Transplantation across full MHC incompatibilities can 
evoke acute rejection. Guttman described hyperacute car-
diac allograft rejection, which was characterized by edema, 
cyanosis, arrhythmia, ventricular fibrillation and finally 
asystole in 4 hours (maximum in 24 hours) after hetero-
topic heart transplantation in recipients previously sensi-
tized with skin transplantation [16]. As mentioned above, 
the acute rejection can be induced across either a class I or 
class II disparity, but class II disparities present a stronger 
barrier to heart transplantation and limit the survival of the 
graft to 10 days. But even in full compatibility in MHC of 
the donor and recipient, the discrepancy of survival time 
varies depending on the organ transplanted. Of note is 
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that the amount of the lymphatic tissue transplanted with 
the heart is considerably smaller than in pancreatic or skin 
transplant, resulting in different expression of the MHC 
antigens. There is also a correlation between the strength 
of the response against a specified MHC antigen and the 
strain. Previous observations [12, 16] showed that the ACI 
strain is highly immunogenic while the Brown Norway (BN) 
rat is a low responder in proliferative reactions to alloan-
tigens in vitro. This observation must be considered when 
planning future research.
Despite the rapid rejection of MHC-mismatched heart 
allografts alone, differences in non-MHC histocompatibility 
antigens also influence the graft survival. The strength of 
the non-MHC barrier is controlled by the immune response 
(Ir) gene, which is extremely variable even from one tissue 
to another and may depend on the number of dendritic 
cells transferred within the transplanted organ. Removal of 
these “passenger cells” may reduce the graft immunoge-
nicity [17].
As previously mentioned, concerning MHC full compat-
ibility Klempnauer et al. described the quicker pancreas 
allograft rejection in the same non-MHC disparate strain 
combination [18]. The number of non-MHC disparities can 
cumulate and determine the strength of the organ rejec-
tion. This process was explained by either additive or in-
dependent interactions, but not by synergy. However, 
Klempnauer et al. described a synergistic effect between 
non-MHC and class I antigens on acute graft rejection [19]. 
Research concerning MHC and non-MHC disparities con-
firmed that there are unpredictable numbers of possible 
combinations of antigens and their products to induce 
heart rejection. The recommended solution to avoid gene 
incompatibilities responsible for acute rejection is to use 
inbred strains, which behave like clones. This may help to 
understand the mechanisms of chronic heart rejection that 
is unrelated to MHC and non-MHC (like Ir in rats) genes. 
The most interesting are differences in the immunological 
response depending on sex combination of the donor and 
recipient, which were observed but difficult to study in het-
erogeneous species such as humans.
Histopathology of the rejection in rats 
The histological scales to assess rejection in explanted 
grafts are the modifications of the International Society for 
Heart and Lung Transplantation rejection scale. The most 
popular is a 3-grade scale described by Barak et al. where, 
after harvesting, preserving in 5% formalin and finally 
embedding the grafts in paraffin, hematoxylin and eosin 
staining is performed. The samples are scored as follows: 
0 – normal; 0.5 – perivascular infiltrate, focal; 1 – perivascu-
lar and interstitial infiltrate, focal; 1.5 – infiltrate, confluent; 
2 – infiltrate associated with necrosis of myocytes; 2.5 – 
diffuse infiltrate, necrosis and edema; 3 – diffuse infiltrate, 
necrosis, edema and hemorrhage [20].
The scale modified by Takami et al. has 5 grades (with-
out grade 2) and is widely used among researchers [21].
Sex differences
There are several publications concerning gender influ-
ence on results in all solid organ transplantation [22–29] as 
a non-immunologic factor. Regitz-Zagrosek et al. showed 
that the sexes differ in distribution of risk factors of heart 
diseases: women more frequently suffer from diabetes and 
hypertension while men more frequently exhibit coronary 
heart disease and dilatative cardiomyopathy. There is also 
a difference in structure – women’s hearts are stiffer and 
smaller, and during aging the processes of fibrosis, apop-
tosis and hypertrophy are less pronounced. Generally, the 
potential causes of this pathway are estrogens; they protect 
myocytes against calcium load induced by hypoxia, increase 
availability of nitric oxide (NO) and impact vasodilatation, 
downregulate fibroblast proliferation and gene expression 
of collagens I and III in females in vitro and decrease ven-
tricular remodeling by matrix metalloproteinase 2 (MMP-2) 
gene expression inhibition [30].
Functional receptors for both estrogen and androgen 
have been found in human and rat hearts: in vascular en-
dothelium, smooth muscle cells of vessel walls, cardiac fi-
broblasts and myocytes, and they influence the effect of 
the sex hormones on the heart. The processes mentioned 
above impact the heart metabolism and may influence the 
result of heart transplantation if there is a sex mismatch 
between donor and recipient. Takami et al. [21] also con-
firmed that pharmacokinetics of cyclosporine, one of the 
immunosuppressive medications used in the rat model of 
heart transplant, differs significantly; blood level in females 
was almost half that of males with contribution to more 
vigorous heart rejection in females. In a subgroup of orchi-
ectomized rats, the suspected immunosuppressant and im-
mune modulation role of the androgens was observed. They 
concluded that female recipients are at greater risk of heart 
rejection irrespective of donor gender and they may require 
stronger immunosuppression treatment. Other researchers 
also observed that females are better donors and males are 
better recipients regardless of the research protocol. 
The sex difference of immune reaction to allograft 
transplantation is a matter of controversy in humans and 
consequently there is no gender matching between donor 
and recipient. In the rat model, using syngeneic animals, 
the immune response based on MHC and non-MHC dispar-
ity can be minimized and non-immunologic factors (such as 
gender-dependent response) investigated. Also, use of rat 
females not presensitized with pregnancies diminishes the 
risk of acute humoral rejection. 
In the shortage of human donors and conflicting results 
in retrospective data, research concerning gender-related 
disparities in matched groups is not possible from an ethi-
cal point of view.
Conclusions
The rat model of heart transplantation is an excellent 
yet underestimated method of research of prevention, 
monitoring and treatment of acute and chronic, immune 
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and non-immune responses to organ or tissue transplan-
tation. It provides the possibility of combining donor and 
recipient sex, and syngeneic or allogenic strains. Despite 
being a technically and logistically demanding model, it 
provides a tool for reproducible experiments with long-
term animal survival and excellent graft survival.
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